Search results
3 sie 2023 · Semaglutide is the active ingredient in the brand-name medications Ozempic and Wegovy. Here’s what to know about its potential for weight loss.
Semaglutide has been shown to increase energy expenditure and promote fat burning, leading to reductions in body weight and improvements in body composition. It may also have a positive impact on lipid metabolism, contributing to favorable changes in cholesterol and triglyceride levels.
10 lut 2021 · Our trial showed that among adults with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide plus lifestyle intervention was associated with substantial, sustained...
Semaglutide could offer an easier and more reliable way to lose weight and combat the health impacts people with obesity face. Why should this drug, proven to work, not be available to help people change their lives?
16 maj 2024 · A new analysis of data from Novo Nordisk’s Select trial indicates that semaglutide (marketed as Wegovy) can enable patients who are overweight or obese to “achieve clinically meaningful weight loss” for at least four years, with fewer serious adverse events than placebo. 1 The analysis, conducted by the manufacturer and published in Nature Medic...
13 maj 2024 · In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years.
14 maj 2024 · The semaglutide-based medicines Ozempic and Wegovy can help people who are obese or overweight to quickly lose weight, but questions remain over how long they should be taken and what other...
